Healthcare >> Sector Roundtables >> July 28, 2003

Roundtable Forum: Biotechnology

Shrader, Thomas
THOMAS SHRADER joined Harris Nesbitt Gerard in 2001 (then Gerard Klauer Mattison) as a Research Analyst in the Healthcare Group, focusing on biotechnology. Previously, he had been a Vice President of Equity Research in Biotechnology at Tucker Anthony Sutro. His prior experience includes research analysis at Oscar Gruss & Son and eight years as a Professor of Biochemistry at the Albert Einstein College of Medicine. He holds a degree in Biophysics from Johns Hopkins University and earned his PhD in Molecular Biophysics and Biochemistry at Yale University. As a Helen Hay Whitney Postdoctoral Fellow in Biology at the Massachusetts Institute of Technology, he conducted research in Molecular Genetics. Profile
MICHAEL G. KING is a Managing Director and Senior Equity Research Analyst in the Health Care Group at Banc of America Securities LLC where he covers the biotechnology sector. He joined Banc of America Securities in 2002 from Robertson Stephens, where he had been a Managing Director and Senior Biotechnology Analyst since 1998. Prior to that, he served as Senior Biotechnology Analyst at Vector Securities from 1996 to 1998 and at Dillon, Read & Co. from 1994 to 1996. He has also held positions at D. Blech & Company, Alex. Brown and Sons, Hambrecht & Quist and Kidder, Peabody & Company. He earned a BBA with honors in Finance from Baruch College. He was ranked fourth for his stock-picking accuracy in The Wall Street Journal's annual 'Best on the Street' survey in 2001 and was given the Institutional Investor Home-Run Hitter award in 2000 for his coverage of OSI Pharmaceuticals. Profile
JENNIFER M. CHAO is a Senior Analyst and Managing Director at RBC Capital Markets. Prior to joining RBC Capital Markets, Ms. Chao was a Senior Analyst at Leerink Swann & Co. Ms. Chao's industry experience includes research at the Columbia Neurological Institute and the Harvard School of Public Health. Ms. Chao was also a research fellow at Harvard Medical School/Massachusetts General Hospital-Department of Medicine as a Biomedical Research Career Award fellow. Ms. Chao received her BA degree in Politics and Greek Classics at New York University and completed a Post-Baccalaureate program in Health Sciences-Genetics at Harvard University. Profile
ERIC SCHMIDT is a Managing Director and Senior Research Analyst at SG Cowen Securities. He joined SG Cowen in 1998 and has been covering biotechnology stocks for eight years. He was a runner-up in biotechnology in the 2001 and 2002 Institutional Investor survey. He was previously a Vice President and Research Analyst for UBS Securities. Before joining UBS, he co-founded Cambridge Biological Consultants, a scientific consulting and research firm. He holds a BA in Chemistry from the University of Pennsylvania and a PhD in Biochemistry from the Massachusetts Institute of Technology. Profile
TWST: Jennifer, what has gone on with these stocks year to date?

Ms. Chao: Year to date the sector has performed exceedingly well. Using

the two major biotech indices, namely the NASDAQ